Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

Principal Financial Group Inc. cut its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) has received a consensus recommendation of “Buy” from the ...

Catalyst Pharmaceuticals, Inc. has announced a settlement agreement with Teva Pharmaceuticals, resolving the patent ...

Its flagship product, Firdapse (amifampridine), is approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS) in adults and children aged six and older. The company also markets Fycompa ...